Levetiracetam Solution
Product Images NDC 16714-358

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 16714-358). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Levetiracetam Fig1)

A bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1,' showing the percentage of patients responding to placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The graph displays approximately 7.4% for placebo, 37.1% for 1000 mg/day, and 39.6% for 3000 mg/day, with statistical significance indicated for Levetiracetam groups versus placebo.*

FDA Label Image

Figure 2 (Levetiracetam Fig2)

A bar chart titled 'Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' showing the percentage of patients achieving at least 50% reduction from baseline. It compares placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day groups, with responder rates of 6.3%, 20.8%, and 35.2%, respectively. Statistical significance versus placebo is noted for both Levetiracetam groups.*

FDA Label Image

Figure 3 (Levetiracetam Fig3)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing placebo and Levetiracetam 3000 mg/day groups. The y-axis shows percentage of patients from 0% to 45%. Placebo group (N=104) has about 14.4% response rate, Levetiracetam group (N=180) has about 39.4% response rate, marked as statistically significant versus placebo.*

FDA Label Image

Figure 4 (Levetiracetam Fig4)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 4' comparing placebo and Levetiracetam treatment groups. The vertical axis shows the percentage of patients, with placebo at 19.6% (N=97) and Levetiracetam at 44.6% (N=101), indicating a higher responder rate for Levetiracetam. An asterisk denotes statistical significance versus placebo.*

FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

A bar chart comparing the responder rate, defined as ≥ 50% reduction from baseline, for patients aged 1 month to under 4 years in Study 5. The chart shows placebo with a responder rate of 19.6% and Levetiracetam with a significantly higher responder rate of 43.1%.*

FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7' comparing the percentage of patients achieving this reduction between placebo and levetiracetam groups. The chart shows 45.2% for placebo (N=84) and 72.2% for levetiracetam (N=79), with a statistical significance indicator for levetiracetam versus placebo.*

FDA Label Image

Package Label-principal Display Panel (100 mg/mL (473 mL Bottle))

Levetiracetam Oral Solution USP 100 mg/mL label displaying the NDC 16714-358. The label includes directions for pharmacists to dispense with a medication guide, storage instructions, manufacturer information (Northstar Rx LLC, Memphis, TN; Aurobindo Pharma Limited, Hyderabad, India), and product volume of 473 mL. It highlights the prescription-only status and the active ingredient strength.*

FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical structure of Levetiracetam, showing its molecular composition with carbon, hydrogen, nitrogen, and oxygen atoms arranged in its characteristic bicyclic ring and side groups associated with the active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.